Germany's DMPs (disease management programmes) ready for take-off
This article was originally published in Clinica
This week saw the launch of regulations for Germany's disease management programmes (DMPs), designed by health minister Ulla Schmidt to provide optimum care to the chronically ill. DMPs for the treatment of diabetes mellitus type II and breast cancer are the first of the initial five projects, planned over the past two years, to officially be given the go-ahead. "The regulations detail the requirements that these programmes must fulfil in order to be authorised by the federal department for insurance," said Ms Schmidt.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.